Inventor · disambiguated record
Brian Harms
Also filed as: HARMS BRIAN
11 granted patents·10 pending applications·109 citations·filing 2009–2023
92Inventor score
Files withMERRIMACK PHARMACEUTICALS INC11SILVER CREEK PHARMACEUTICALS INC7NIELSEN ULRIK2SCHOEBERL BIRGIT1
Top patents by PatentIndex Score
21 records- 0195US9238080B2Bi-specific fusion proteinsNIELSEN ULRIK·Filed 2011·Granted Jan 19, 2016·29 cites·21 claims
- 0294US10988547B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·6 cites·7 claims
- 0394US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0494US8691771B2Bi-specific fusion proteins for tissue repairNIELSEN ULRIK·Filed 2011·Granted Apr 8, 2014·21 cites·9 claims
- 0593US10858450B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·6 cites·7 claims
- 0693US10407512B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·9 cites·8 claims
- 0791US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 0890US11814443B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·1 cites·20 claims
- 0989US2024101713A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1088US11673970B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Jun 13, 2023·1 cites·7 claims
- 1187US8623592B2Methods and systems for predicting response of cells to a therapeutic agentSCHOEBERL BIRGIT·Filed 2009·Granted Jan 7, 2014·9 cites·11 claims
- 1287US2023322951A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1382US9458245B2ANTI-C-MET tandem Fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·6 cites·3 claims
- 1467US2014127238A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1558US2017307631A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1657US2011027291A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 1753US2014294834A1Tandem fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1849US2017081421A1Anti-c-met tandem fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1947US2011125468A1Using response surfaces for screening inhibitor combinations and digital processing methodsMERRIMACK PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 2047US2017218028A1Tandem fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2133US2017306415A1Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-metMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brian Harms files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →